The conjugated anti-CD33 monoclonal antibody, gemtuzumab ozogamicin (GO), is highly active against acute myeloid leukemia (AML), but dosing and scheduling issues have bedeviled its stable integration into routine clinical care regimens. Here, CD33 is linked to acute myeloid leukemia.